HVL PHARMA UK LTD

• ◆

  6 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

1. HVL PHARMA UK LTD 2025-09-22 → present
2. EUROAPI UK LIMITED 2021-05-04 → 2025-09-22
3. GENZYME LIMITED 1991-09-30 → 2021-05-04
4. GENZYME (UK) LIMITED 1981-12-31 → 1991-09-30
5. HONEYWORTH LIMITED 1981-04-21 → 1981-12-31

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

BDO LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors have reviewed the company's forecast cash flows for a period of at least 12 months from the date of approval of these financial statements, which show that the Company is expected to generate cash inflows (with the support of cash injections from the parent company). The Company's cash position is managed locally by the financial team. The Directors have received confirmation from its ultimate holding company, Particle Dynamics Holdings, Inc of its intention to provide such financial support as the Company requires for a period of at least 12 months from the date of approval of the financial statements. Based on current forecasts and strategic developments, the Directors consider that the longer-term going concern risk is low, and they expect the Company to return to profitability in due course.”

Significant events

• “The Directors identify the primary risk and uncertainty as potential disruptions to the Company's product supply and its own manufacturing and processing facilities. Increasing generic competition for the two main products manufactured by the Company is impacting demand and creating uncertainty in the medium to longer term.”
• “The Company is exposed to foreign exchange risk due to the mismatch between its revenue and cost base, with most of the income denominated in euros (EUR) and most expenses incurred in pounds sterling (GBP).”
• “A major investment has been undertaken in 2023 to install a 1.6 MW solar farm on the site on Rookwood Way, this was operational in early 2024.”
• “On 30 June 2025, the Company was successfully sold to a US based company called Particle Dynamics. Particle Dynamics is a global leader in particle processing and delivery technologies.”
• “On 22 September 2025 the name of the Company was changed from EuroAPI UK Limited to HVL Pharma UK Ltd.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

2

last 24 months

Officers appointed

3

last 12 months

Officers resigned

6

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -35.6%

  £50,727,000 → £32,672,000

  lowest in 4 filed years

• Cash

  +70.9%

  £1,071,000 → £1,830,000

  highest in 4 filed years

• Net assets

  -58.8%

  £10,005,000 → £4,120,000

  lowest in 4 filed years

• Employees

  -20.3%

  237 → 189

  lowest in 4 filed years

• Operating profit

  +87.1%

  -£45,476,000 → -£5,865,000

• Profit before tax

  +86.2%

  -£45,724,000 → -£6,308,000

• Wages

  -4.5%

  £14,516,000 → £13,863,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers